Global Tissue Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2025 –2031 |
 Market Size (Base Year) |
USD 565.62 Million |
 Market Size (Forecast Year) |
USD 943.15 Million |
 CAGR |
% |
| Major Markets Players |
|
>全球组织诊断市场，按产品（消耗品和仪器）、技术（免疫组织化学、原位杂交、数字病理学和工作流程管理以及特殊染色）、疾病（乳腺癌、胃癌、淋巴瘤、前列腺癌、非小细胞肺癌和其他疾病）、最终用户（医院、制药公司、研究实验室、诊断中心、门诊手术中心等）划分——行业趋势和预测到 2031 年。
组织诊断市场分析和规模
组织诊断市场的发展得益于能够准确识别器官和肿瘤组织疾病的技术进步。它用于诊断和评估各种疾病，包括癌症、传染病、自身免疫性疾病和遗传病。此外，该市场的主要参与者投资于研发以创新诊断技术，从而提高市场竞争力。例如，罗氏诊断投资开发先进的组织诊断解决方案，例如 VENTANA PD-L1 (SP142) 检测。该检测有助于诊断某些类型的癌症并预测对免疫疗法的反应，从而促进市场增长。
2023 年全球组织诊断市场规模价值 5.6562 亿美元，预计到 2031 年将达到 9.4315 亿美元，2024 年至 2031 年预测期内的复合年增长率为 6.6%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge 市场研究团队策划的市场报告还包括深入的专家分析、进出口分析、定价分析、生产消费分析、专利分析和消费者行为。
组织诊断市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
产品（耗材及仪器）、技术（免疫组织化学、原位杂交、数字病理学及工作流程管理、特殊染色）、疾病（乳腺癌、胃癌、淋巴瘤、前列腺癌、非小细胞肺癌及其他疾病）、最终用户（医院、制药公司、研究实验室、诊断中心、门诊手术中心及其他） |
|
覆盖国家 |
美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区 |
|
涵盖的市场参与者 |
F. Hoffmann-La Roche Ltd (Switzerland), Danaher (U.S.), Thermo Fisher Scientific (U.S.), Abbott (U.S.), Agilent Technologies Inc. (U.S.), Merck KGaA (U.S.), Sakura Finetek Japan Co. Ltd. (U.S.), BD (U.S.), QIAGEN (Germany), Bio SB (U.S.), BioGenex. (U.S.), Abcam Limited (U.K.), Cell Signaling Technology Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), The Menarini Group (Italy), Enzo Life Sciences, Inc. (U.S.), Zenalux Biomedical, Inc. (U.S.), Lunaphore Technologies SA. ((Switzerland), 3DHISTECH Ltd. (Hungary), Lunaphore Technologies (Switzerland), Biocare Medical, LLC. (U.S.), ., and Genomic Health Inc.(U.S.) among others |
|
Market Opportunities |
|
Market Definition
Tissue diagnostics involves examining tiny samples of body tissues to identify diseases such as cancer. Doctors take tissue samples through biopsies or surgeries. These samples are then analyzed under a microscope to look for abnormal cells or structures. Tissue diagnostics helps doctors make accurate diagnoses and determine the best treatment options for patients.
Tissue Diagnostics Market Dynamics
Drivers
- Rising Demand for Diagnostic Testing Services
With aging populations and changing lifestyles contributing to the growing disease burden, there is an urgent need for effective diagnostic solutions. This surge in demand, reflected in the expanding cancer market size, underscores the importance of early detection for successful treatment outcomes. Tissue diagnostics through techniques such as biopsies and molecular testing, plays a pivotal role in accurately identifying cancer types and guiding treatment decisions.
For instance,
- GRAIL has initiated non-invasive blood tests that analyze circulating tumor DNA, allowing for the detection of cancer at its earliest stages. This breakthrough technology showcases the critical role of tissue diagnostics in improving cancer detection rates and treatment outcomes
As a result, the market for tissue diagnostics continues to expand rapidly to meet the rising healthcare demands worldwide.
- Growing Demand for Personalized Medicine
The growing demand for personalized medicine is driven by advancements in molecular and genetic technologies, enabling tailored treatment strategies based on individual patient characteristics. This approach considers genetic makeup, lifestyle factors, and disease biomarkers to optimize treatment efficacy and minimize adverse effects. Patients increasingly seek personalized therapies that offer higher efficacy rates and fewer side effects compared to traditional treatments.
For instance,
- Foundation Medicine has created comprehensive genomic profiling tests that analyze tumor DNA to identify specific mutations and guide treatment decisions. This approach enables oncologists to prescribe personalized therapies tailored to the patient's unique genetic profile, leading to improved treatment outcomes and patient satisfaction
In addition, healthcare providers recognize the potential cost savings and improved patient outcomes associated with personalized medicine, further fueling its adoption and driving market growth in the healthcare industry.
Opportunities
- Strategic Collaborations and Partnerships with Healthcare Providers
Pharmaceutical companies often collaborate with biotechnology firms or academic institutions to access novel technologies, drug candidates, or research insights. Similarly, diagnostic companies may form partnerships with healthcare providers or data analytics firms to enhance diagnostic accuracy and expand market reach.
For instance,
- AstraZeneca partnered with Merck & Co. to develop and commercialize Lynparza (olaparib) as a potential treatment for multiple cancer types. This collaboration combines AstraZeneca's expertise in oncology with Merck's global reach, accelerating drug development and expanding patient access to advanced cancer treatments
These collaborations facilitate the development of new therapies, diagnostic tools, and treatment approaches, ultimately benefiting patients by improving healthcare outcomes. Furthermore, strategic alliances enable companies to navigate regulatory challenges more effectively, accelerate product development timelines, and capitalize on emerging market opportunities, thereby driving growth and competitiveness in the tissue diagnostic sector.
- Increasing Geriatric Population Impacts Demand for Tissue Diagnostics
As individuals age, they become more susceptible to various diseases, including cancer and degenerative conditions. Tissue diagnostics play a crucial role in diagnosing these age-related illnesses, enabling early detection and personalized treatment strategies. With a growing number of elderly individuals requiring diagnostic services, the demand for tissue diagnostics rises accordingly. This demographic trend drives market growth in the tissue diagnostics sector, highlighting the importance of catering to the healthcare needs of aging populations.
Restraints/Challenges
- Infrastructure Limitations in Developing Regions
Infrastructure limitations in developing regions, such as inadequate laboratory facilities, unreliable electricity supply, and limited access to specialized equipment, hinder the effectiveness of tissue diagnostics. Without proper infrastructure, tissue samples may be mishandled or improperly stored, leading to inaccurate results Limited access to reliable electricity, clean water, and proper waste disposal facilities further hinders the implementation of tissue diagnostics technologies. As a result, healthcare providers struggle to offer timely and accurate diagnostic services, leading to delays in diagnosis, treatment, and disease management. Additionally, infrastructure constraints impede the penetration of tissue diagnostics solutions into these regions, limiting market growth opportunities and exacerbating healthcare disparities between developed and developing economies.
- Lack of Skilled Personnel for Analyzer Operation
Advanced diagnostic analyzers require specialized training and expertise to operate effectively, interpret results accurately, and troubleshoot technical issues. However, the shortage of skilled personnel hampers the adoption and utilization of these sophisticated technologies, leading to suboptimal performance and reduced efficiency in diagnostic laboratories. This constraint not only impedes the timely delivery of diagnostic services but also limits the market potential for tissue diagnostics solutions, as healthcare facilities may struggle to fully leverage the benefits of these innovative tools without adequately trained staff.
This tissue diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global Tissue Diagnostics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In May 2022, Leica Biosystems (Nussloch, Germany) launched a compact, dual-retort tissue processor, the HistoCore PEGASUS Plus. Its compact design and dual-retort system enhance laboratory workflow, improving efficiency and throughout. This innovation drives the adoption of tissue processing technology, stimulating market expansion and innovation
- In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research. This innovative kit enhances researchers' ability to detect multiple biomarkers simultaneously, advancing understanding and diagnosis of cancer, thereby driving demand for immunohistochemistry solutions and fostering market expansion
Tissue Diagnostics Market Scope
The tissue diagnostics market is segmented into four notable segments based on product, technology, disease, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Consumables
- Instruments
Technology
- Immunohistochemistry
- In Situ Hybridization
- Digital Pathology and Workflow Management
- Special Staining
Disease
- Breast Cancer
- Gastric Cancer
- Lymphoma
- Prostate Cancer
- Non-Small Cell Lung Cancer
- Other Diseases
End User
- Hospitals
- Pharmaceutical Companies
- Research Laboratories
- Diagnostic Centres
- Ambulatory Surgical Centres
- Others
Tissue Diagnostics Market Regional Analysis/Insights
The tissue diagnostics market is analysed and market size insights and trends are provided by based on product, technology, disease, and end user as referenced above.
The countries covered in the tissue diagnostics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America dominates the tissue diagnostics market because of the rising prevalence of cancer in the region and growing investment in healthcare infrastructure. The presence of several public programs aims to minimize cancer incidences and raise the demand for cancer diagnosis in the regional market. The Cancer Prevention and Control Research Network is a flagship program by the Centers for Disease Control and Prevention that focuses on cancer prevention in this region.
Asia-Pacific is expected to be the fastest-growing region in the tissue diagnostic market due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
组织诊断市场还为您提供了详细的市场分析，包括每个国家/地区资本设备医疗支出的增长、组织诊断市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗监管情景的变化及其对组织诊断市场的影响。数据适用于 2016-2021 年的历史时期。
竞争格局和组织诊断市场份额分析
组织诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对组织诊断市场的关注有关。
组织诊断市场的一些主要参与者包括：
- F. Hoffmann-La Roche Ltd（瑞士）
- 丹纳赫（美国）
- 赛默飞世尔科技（美国）
- 雅培（美国）
- 安捷伦科技公司（美国）
- 默克集团（美国）
- Sakura Finetek Japan Co. Ltd.（美国）
- BD（美国）
- QIAGEN（德国）
- Bio SB（美国）
- BioGenex.(美国)
- Abcam 有限公司 (英国)
- Cell Signaling Technology Inc.（美国）
- Koninklijke Philips NV（荷兰）
- 美纳里尼集团（意大利）
- Enzo Life Sciences, Inc.（美国）
- Zenalux Biomedical, Inc.（美国）
- 3DHISTECH 有限公司 (匈牙利)
- Lunaphore Technologies SA.（瑞士）
- Biocare Medical, LLC.（美国）
- Genomic Health, Inc.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
